Aaron T. Gerds, MD, MS

New research unveils a promising monoclonal antibody therapy targeting CALR mutations in essential thrombocythemia, aiming to improve patient outcomes.

Early data show promising platelet and molecular responses with monoclonal antibody monotherapy in ET and MF, with trials ongoing in the US and abroad.

Aaron T. Gerds, MD, discusses a new therapeutic approach for essential thrombocythemia, a less-common myeloproliferative neoplasm.

Aaron T. Gerds, MD, discusses the unmet needs in the treatment of essential thrombocythemia, as well as novel methods for approaching disease treatment.

Panelists discuss how recent clinical trial data and emerging therapeutic options are reshaping the treatment paradigm for myelofibrosis, requiring thoughtful integration of new evidence into current clinical practice guidelines.

Panelists discuss how treatment sequencing decisions in myelofibrosis should be guided by clinical evidence, patient response patterns, and strategic consideration of future therapeutic options to maintain long-term disease control.

Panelists discuss how the timing of therapeutic interventions in early-stage myelofibrosis must be carefully weighed against potential risks and benefits, with consideration of disease trajectory and patient-specific factors to optimize long-term outcomes.

Panelists discuss how complex cases of advanced myelofibrosis can be managed using evidence-based treatment algorithms, considering factors such as disease progression, prior therapies, and challenging complications.

Panelists discuss how clinicians can effectively manage patients with high-risk myelofibrosis with cytopenias through careful treatment selection, dose modification strategies, and monitoring of hematologic parameters.

Panelists discuss how clinical trial data inform the selection of second-line therapies for patients with myelofibrosis, focusing on response assessment criteria and identifying optimal candidates for various treatment options.

Panelists discuss how myelofibrosis can evolve following initial treatment, examining common patterns of disease progression and strategies for adapting therapeutic approaches based on individual patient response and changing clinical parameters.

Panelists discuss how the landmark COMFORT trials have shaped the understanding of Janus kinase inhibitor therapy response criteria and long-term clinical outcomes in patients with myelofibrosis, providing crucial data to inform current treatment approaches.

Panelists discuss how risk stratification tools and patient-specific factors guide treatment selection and timing of interventions for patients with newly diagnosed intermediate 2–risk myelofibrosis, with a focus on optimizing clinical outcomes.

Panelists discuss how health care providers can optimize quality-of-life and treatment outcomes for patients with myelofibrosis through comprehensive symptom management, shared decision-making, and careful attention to patient goals and expectations.

Panelists discuss how myelofibrosis progresses from its molecular and genetic origins through various clinical manifestations, ultimately informing the development of targeted therapeutic approaches for this bone marrow disorder.

Aaron Gerds, MD, MS, shares hopes that combination therapies now in trials, along with other novel approaches further down the pipeline like monoclonal antibodies, vaccines, and cellular therapies will likely radically advance treatment over the next 5 to 10 years.

Aaron Gerds, MD, MS, reviews key safety concerns seen with JAK inhibitors for myelofibrosis treatment.

Aaron Gerds, MD, MS, explains the factors to consider when selecting an appropriate JAK inhibitor for patients with myelofibrosis.

When switching JAK inhibitors for myelofibrosis, Aaron Gerds, MD, MS, advises stopping ruxolitinib and starting the new JAK inhibitor the next day due to its short half-life, though tapering ruxolitinib over 1 week is recommended for patients on higher doses to avoid rebound symptoms; pacritinib and fedratinib have longer half-lives so a 1-week washout can be considered.

Aaron Gerds, MD, MS, explains that myelofibrosis patients on JAK inhibitors need regular monitoring of blood counts, liver enzymes, and cardiac events to check for reactivation.

Aaron Gerds, MD, MS, details the use of momelotinib in myelofibrosis treatment.

Aaron Gerds, MD, MS, outlines how first-line treatment choice for myelofibrosis depends on symptoms, spleen size, and blood counts, while second-line choice depends on prior side effects and medical history.

Aaron Gerds, MD, MS, explains that unlike solid tumors, blood cancers are systemic, so risk stratification models like DIPSS that use readily available data on blood counts and physical exam are more useful prognostically; however, mutation analysis is becoming increasingly important for determining prognosis and targeting therapies.

Aaron Gerds, MD, MS, presents the case of a 73-year-old man with myelofibrosis.

Aaron T. Gerds, MD, MS, discusses available treatment options for patients with myelofibrosis and some of the agents that are currently under development, inching toward regulatory approval in the field of myelofibrosis.

Aaron T. Gerds, MD, MS, provides advice to community oncologists on how to utilize momelotinib for patients with myelofibrosis.

Results of the phase 3 MOMENTUM study showed that the JAK1/JAK2 inhibitor momelotinib can provide treatment for the patient’s disease and also their anemia.

Aaron T. Gerds, MD, MS, highlights exciting treatment options on the horizon for patients with myelofibrosis.

Aaron T. Gerds, MD, MS, explains the current remaining unmet needs in the treatment of patients with myelofibrosis.

Aaron T. Gerds, MD, MS, details the current treatment options available for patients with high-risk myelofibrosis, and reviews the criteria for risk stratification.